Biomark to Expand Treatment Response Trial to Advanced Lung Cancer Patient Receiving Immunotherapy
![iucpq laval press release biomark diagnostics](https://www.biomarkdiagnostics.com/wp-content/uploads/2021/06/iucpq-and-laval-logo-press-release-image-biomark-diagnostics.jpg)
Vancouver, British Columbia – (June 29th, 2021) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that Health Canada has approved its clinical trial application (CTA) and has granted a Letter of No Objection (NOL) for its application entitled Excretion of Acetylamantadine (AA) by Lung Cancer Patients During a […]
Quest for Game Changing Lung Cancer Diagnostic Assay
![Quest for Game Changing Lung Cancer Diagnostic Assay](https://www.biomarkdiagnostics.com/wp-content/uploads/2015/09/Quest-for-Game-Changing-Lung-Cancer-Diagnostic-Assay.jpg)
HealthTech Innovation Hub and Surrey Memorial Hospital Rashid Ahmed, President & CEO Dr. James Bond, Chief of Thoracic Surgery, Surrey Memorial Hospital